# Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

> **NCT04742959** · PHASE1,PHASE2 · COMPLETED · sponsor: **TransThera Sciences (Nanjing), Inc.** · enrollment: 203 (actual)

## Conditions studied

- Advanced Solid Tumor
- Cholangiocarcinoma
- HER2-negative Breast Cancer
- Triple Negative Breast Cancer
- Bladder Cancer
- Small-cell Lung Cancer
- Prostate Cancer
- Thyroid Cancer
- Sarcoma
- Gastric Cancer
- Gallbladder Cancer

## Interventions

- **DRUG:** TT-00420
- **COMBINATION_PRODUCT:** Nab-Paclitaxel

## Key facts

- **NCT ID:** NCT04742959
- **Lead sponsor:** TransThera Sciences (Nanjing), Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-14
- **Primary completion:** 2024-02-20
- **Final completion:** 2024-02-20
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2024-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04742959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04742959, "Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04742959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*